The U.K.'s cost-effectiveness agency is recommending much broader use of statin drugs now that they are available as cheaper generics. A similar call in the U.S. touched off a debate over preventive use of the meds. The recommendation would put millions more patients on cholesterol-lowering pills, and could boost the size of the market for branded drugs, such as AstraZeneca's ($AZN) Crestor. Report